Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/28711
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Albrecht, Philipp | - |
dc.contributor.author | Bjorna, Ingrid Kristine | - |
dc.contributor.author | Brassat, David | - |
dc.contributor.author | Farrell, Rachel | - |
dc.contributor.author | FEYS, Peter | - |
dc.contributor.author | Hobart, Jeremy | - |
dc.contributor.author | Hupperts, Raymond | - |
dc.contributor.author | Linnebank, Michael | - |
dc.contributor.author | Magdic, Jozef | - |
dc.contributor.author | Oreja-Guevara, Celia | - |
dc.contributor.author | Pozzilli, Carlo | - |
dc.contributor.author | Salgado, Antonio Vasco | - |
dc.contributor.author | Ziemssen, Tjalf | - |
dc.date.accessioned | 2019-07-15T12:20:24Z | - |
dc.date.available | 2019-07-15T12:20:24Z | - |
dc.date.issued | 2018 | - |
dc.identifier.citation | Therapeutic Advances in Neurological Disorders, 11, p. 1-8 | - |
dc.identifier.issn | 1756-2856 | - |
dc.identifier.uri | http://hdl.handle.net/1942/28711 | - |
dc.description.abstract | Prolonged-release (PR) fampridine is the only approved medication to improve walking in multiple sclerosis (MS), having been shown to produce a clinically meaningful improvement in walking ability in the subset of MS patients with Expanded Disability Status Scale 4-7. Recent responder subgroup analyses in the phase III ENHANCE study show a large effect size in terms of an increase of 20.58 points on the patient-reported 12-item MS Walking Scale in the 43% of patients classified as responders to PR-fampridine, corresponding to a standardized response mean of 1.68. Use of PR-fampridine in clinical practice varies across Europe, depending partly on whether it is reimbursed. A group of European MS experts met in June 2017 to discuss their experience with using PR-fampridine, including their views on the patient population for treatment, assessment of treatment response, re-testing and retreatment, and stopping criteria. This article summarizes the experts' opinions on how PRfampridine can be used in real-world clinical practice to optimize the benefits to people with MS with impaired walking ability. | - |
dc.description.sponsorship | The expert meeting was supported financially by Biogen, Baar, Switzerland. | - |
dc.language.iso | en | - |
dc.publisher | SAGE PUBLICATIONS LTD | - |
dc.rights | The Author(s), 2018. Article reuse guidelines: sagepub.com/journalspermissions Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License | - |
dc.subject.other | multiple sclerosis; prolonged-release fampridine; real-world experience; treatment response; walking ability | - |
dc.subject.other | multiple sclerosis; prolonged-release fampridine; real-world experience; treatment response; walking ability | - |
dc.title | Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 8 | - |
dc.identifier.spage | 1 | - |
dc.identifier.volume | 11 | - |
local.format.pages | 8 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | [Albrecht, Philipp] Heinrich Heine Univ, Med Fac, Dept Neurol, Moorenstr 5, D-40225 Dusseldorf, Germany. [Bjorna, Ingrid Kristine] Vestre Viken, Drammen Sykehus, Neurol Dept, Drammen, Germany. [Brassat, David] Univ Toulouse III, CHU Toulouse, SEP, Ctr Resource & Competence, Toulouse, France. [Brassat, David] Univ Toulouse III, UMR1043, Toulouse, France. [Farrell, Rachel] UCL Inst Neurol, Dept Neuroinflammat, London, England. [Farrell, Rachel] UCLH NHS Fdn Trust, Natl Hosp Neurol & Neurosurg, London, England. [Feys, Peter] Hasselt Univ, Fac Rehabil Sci, BIOMED, REVAL, Hasselt, Belgium. [Hobart, Jeremy] Plymouth Univ Peninsula, Sch Med, Dept Clin Trials & Hlth Res Translat & Stratified, Plymouth, Devon, England. [Hobart, Jeremy] Plymouth Univ Peninsula, Sch Dent, Dept Clin Trials & Hlth Res Translat & Stratified, Plymouth, Devon, England. [Hupperts, Raymond] Zuyderland Med Ctr, Dept Neurol, Sittard Geleen, Netherlands. [Linnebank, Michael] Helios Clin Hagen Ambrock, Dept Neurol, Hagen, Germany. [Magdic, Jozef] Univ Med Ctr Maribor, Dept Neurol, Maribor, Slovenia. [Oreja-Guevara, Celia] Univ Complutense Madrid, Dept Med, Hosp Clin San Carlos, Neurol, Madrid, Spain. [Oreja-Guevara, Celia] Inst Invest Sanitaria Hosp Clin San Carlos IdISSC, Madrid, Spain. [Pozzilli, Carlo] Univ Roma La Sapienza, Dept Neurol, Rome, Italy. [Salgado, Antonio Vasco] Hosp Fernando Fonseca, Serv Neurol, Amadora, Portugal. [Ziemssen, Tjalf] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, MS Ctr Dresden, Ctr Clin Neurosci,Dept Neurol, Dresden, Germany. | - |
local.publisher.place | LONDON | - |
local.type.refereed | Refereed | - |
local.type.specified | Review | - |
dc.identifier.doi | 10.1177/1756286418803248 | - |
dc.identifier.isi | 000455655900001 | - |
item.validation | ecoom 2020 | - |
item.fulltext | With Fulltext | - |
item.accessRights | Open Access | - |
item.fullcitation | Albrecht, Philipp; Bjorna, Ingrid Kristine; Brassat, David; Farrell, Rachel; FEYS, Peter; Hobart, Jeremy; Hupperts, Raymond; Linnebank, Michael; Magdic, Jozef; Oreja-Guevara, Celia; Pozzilli, Carlo; Salgado, Antonio Vasco & Ziemssen, Tjalf (2018) Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting. In: Therapeutic Advances in Neurological Disorders, 11, p. 1-8. | - |
item.contributor | Albrecht, Philipp | - |
item.contributor | Bjorna, Ingrid Kristine | - |
item.contributor | Brassat, David | - |
item.contributor | Farrell, Rachel | - |
item.contributor | FEYS, Peter | - |
item.contributor | Hobart, Jeremy | - |
item.contributor | Hupperts, Raymond | - |
item.contributor | Linnebank, Michael | - |
item.contributor | Magdic, Jozef | - |
item.contributor | Oreja-Guevara, Celia | - |
item.contributor | Pozzilli, Carlo | - |
item.contributor | Salgado, Antonio Vasco | - |
item.contributor | Ziemssen, Tjalf | - |
crisitem.journal.issn | 1756-2856 | - |
crisitem.journal.eissn | 1756-2864 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
albrecht 1.pdf | Published version | 102.07 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.